6401 Hollis Street
About Santen, Inc.
Santen is a global pharmaceutical and medical device company focused solely on ophthalmology. We’re committed to serving serious unmet needs by developing innovative solutions that protect vision and, in turn, preserve quality of life for people around the world.
Santen USA, located in Emeryville, CA, is an important part of our ophthalmic research, development, and commercialization efforts worldwide and the home of our regional business teams. By leveraging our deep industry knowledge and a network of external partners, we aim to deliver game-changing therapies and make hope a reality for people facing vision impairment and loss.
Our deep roots start in Japan, Santen’s worldwide headquarters, where the company began in 1890. Since then, Santen has become an established leader in the Asian and European prescription ophthalmology marketplaces and continues to expand across global markets, including the United States. Today, Santen employs more than 4,000 people worldwide and sells specialty ophthalmic products in more than 60 countries.
With a clear focus on vision, we aim to deliver the highest quality products, to act with integrity, to earn the trust of our partners and customers, and to deliver sight-saving innovations to physicians and patients who are waiting for them.
32 articles with Santen, Inc.
European Medicines Agency Accepts Santen, Inc.'s Marketing Application Filing For Intravitreal Sirolimus For The Treatment Of Noninfectious Uveitis Of The Posterior Segment
DURECT Corporation Enters Into License Agreement Granting Santen, Inc. The Worldwide Rights To A Sustained Release SABER Ophthalmology Product
NicOx SA: Santen, Inc. Grants EuPharmed Extension Of Exclusive Rights To Distribute Cationorm® In Italy
Santen, Inc. Phase 3 Study Meets Primary Endpoint For The Treatment Of Non-Infectious Posterior Segment Uveitis (NI-PSU)
Santen Pharmaceutical Announces the Appointment of Naveed Shams, M.D., Ph.D. as the President and CEO
Santen, Inc. Announces European Medicines Evaluation Agency Orphan Drug Status for Sirolimus (DE-109)
Clinical Data, Inc. Receives Notice of IND Filing by Santen, Inc. and Upcoming $2 Million Milestone Payment for A2A Agonist Development Program Focused on Glaucoma Treatments
Santen, Inc. Announces Preliminary Results Of Overseas Clinical Trials Of Two Glaucoma Drug Candidates; DE-092 Efficacy Insufficient